Manufacturer
NOVARTIS PHARMA STEIN A.G.
Contents
Ceritinib
Indication
ALK-positive metastatic non-small cell lung carcinoma.
Instruction
Should be taken with food. Take at the same time each day.
Drug interaction
Increased risk of QTc prolongation with antiarrhythmics (e.g. quinidine). Enhanced hyperglycaemic effect with corticosteroids. Increased exposure with strong CYP3A inhibitors (e.g. ketoconazole, ritonavir, telithromycin, nefazodone). Decreased exposure with strong CYP3A inducer (e.g. carbamazepine, phenobarbital, rifampicin). May decrease bioavailability with proton pump inhibitors, H2-receptor antagonists, antacids. May increase serum concentration of CYP3A substrates (e.g. ciclosporin, ergotamine, fentanyl, pimozide), CYP2C9 substrates (e.g. phenytoin, warfarin).Potentially Fatal: Increased risk of bradycardia with β-blockers, non-dihydropyridine calcium channel blockers (e.g. diltiazem), clonidine, digoxin.
Malaysia
